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ABSTRACT
Introduction Herpes simplex virus (HSV) infection can 
cause painful, recurrent genital ulcer disease (GUD), which 
can have a substantial impact on sexual and reproductive 
health. HSV- related GUD is most often due to HSV type 2 
(HSV-2), but may also be due to genital HSV type 1 (HSV-1), 
which has less frequent recurrent episodes than HSV-2. 
The global burden of GUD has never been quantified. Here 
we present the first global and regional estimates of GUD 
due to HSV-1 and HSV-2 among women and men aged 
15–49 years old.
Methods We developed a natural history model reflecting 
the clinical course of GUD following HSV-2 and genital 
HSV-1 infection, informed by a literature search for data 
on model parameters. We considered both diagnosed and 
undiagnosed symptomatic infection. This model was then 
applied to existing infection estimates and population sizes 
for 2016. A sensitivity analysis was carried out varying the 
assumptions made.
Results We estimated that 187 million people aged 
15–49 years had at least one episode of HSV- related GUD 
globally in 2016: 5.0% of the world’s population. Of these, 
178 million (95% of those with HSV- related GUD) had HSV-
2 compared with 9 million (5%) with HSV-1. GUD burden 
was highest in Africa, and approximately double in women 
compared with men. Altogether there were an estimated 
8 billion person- days spent with HSV- related GUD globally 
in 2016, with 99% of days due to HSV-2. Taking into 
account parameter uncertainty, the percentage with at 
least one episode of HSV- related GUD ranged from 3.2% 
to 7.9% (120–296 million). However, the estimates were 
sensitive to the model assumptions.
Conclusion Our study represents a first attempt to 
quantify the global burden of HSV- related GUD, which is 
large. New interventions such as HSV vaccines, antivirals 
or microbicides have the potential to improve the quality of 
life of millions of people worldwide.
InTRoduCTIon
Genital herpes is a lifelong sexually trans-
mitted infection caused by herpes simplex 
virus type 2 (HSV-2) and type 1 (HSV-1) and 
is characterised by recurrent, self- limited 
outbreaks of painful genital lesions in a 
proportion of those infected.1 We estimated 
that in 2016, 491 million people aged 15–49 
years had HSV-2 infection, which is almost 
all sexually transmitted.2 HSV-1, although 
predominately an oral infection, is increasing 
as a cause of genital herpes in some 
settings.3–5 We estimated that 192 million 
Key questions
What is already known?
 ► Herpes simplex virus (HSV) type 2 infections are 
abundant globally and can cause painful, recurrent 
genital ulcer disease (GUD), the natural history of 
which has been well documented.
 ► Genital HSV type 1 infection also causes GUD, but 
recurrences tend to be much less frequent.
 ► The population burden of GUD, given global esti-
mates of HSV infection and the known natural his-
tory of GUD, has never been quantified.
What are the new findings?
 ► Using a natural history model applied to infection 
estimates and population sizes, we estimated that 
187 million people (5.0% of the world’s population) 
aged 15–49 years had at least one episode of HSV- 
related GUD globally in 2016, with an estimated 
8 billion person- days spent with HSV- related GUD in 
this year.
 ► GUD burden was highest in Africa, approximately 
double in women compared with men, and almost 
entirely due to HSV type 2.
What do the new findings imply?
 ► The global burden of HSV- related GUD is large and 
affects all regions of the world, although dispropor-
tionately affects certain populations.
 ► Interventions targeted against HSV, such as new 
vaccines, antivirals or microbicides, have the poten-
tial to improve the quality of life of millions of people 
worldwide.
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Figure 1 Flow chart showing the different possible GUD 
states relevant to the GUD estimates. Please refer to table 1 
for definitions of terms, and online supplementary table 
A1 for information on how these states map to the natural 
history parameters used in the GUD burden estimates. Note 
that this is a simplified representation for the purposes of the 
estimation process. GUD, genital ulcer disease; HSV, herpes 
simplex virus.
people had genital HSV-1 infection in 2016.2 Symptoms 
of genital HSV infection include vesicles, ulcers, fissures 
or other painful lesions on or near the genital skin and 
mucosa, collectively termed genital ulcer disease (GUD). 
Although many people acquire genital HSV infection 
without symptoms, in those who do have GUD, the first 
episode typically lasts the longest (up to 2–3 weeks in the 
absence of antiviral therapy) and may be more severe and 
associated with systemic symptoms.6 First- episode GUD 
is clinically indistinguishable whether caused by HSV-2 
or HSV-1 infection.6 However, those with HSV-2- related 
GUD often have subsequent periodic recurrences of 
GUD over many years, while HSV-1- related GUD seems 
to recur much less frequently.7 GUD recurrences tend to 
be shorter and less severe than the first episode.6 7
Symptomatic HSV infection is associated with psycho-
social effects, including low mood, feelings of shame and 
stigma, fears around transmission, and effects on personal 
relationships.8 There is potential for transmission to 
sexual partners, and to the neonate during birth, regard-
less of symptoms, as viral shedding occurs both asymp-
tomatically and symptomatically.9–11 Neonatal infection 
is rare but can be extremely serious, as it carries a high 
risk of neonatal death or permanent disability.12 Current 
epidemiological evidence suggests that HSV-2 infection 
also increases susceptibility to HIV infection,13 14 and may 
increase HIV infectiousness in people living with HIV 
(PLHIV).13 15 16 Since GUD is associated with increased 
quantities of viral shedding, as well as breaches to the 
protective integrity of the genital skin and mucosa, these 
transmission risks and cofactor effects may be heightened 
in the presence of GUD.17
The global burden of HSV- related GUD is not well 
understood due to a lack of dependable, systematic 
surveillance or prevalence studies in most settings. Case 
reporting may not be reliable because many symptomatic 
individuals do not seek care and remain undiagnosed,18 
and GUD may not be recognised as herpetic by clini-
cians, since although HSV is the most common cause of 
GUD globally GUD can have other causes.19–26 A more 
complete understanding of the morbidity associated with 
HSV infection, and in particular GUD, would help eluci-
date the full potential public health value of HSV inter-
ventions.27 Here we present the first global and regional 
estimates of GUD due to HSV-1 and HSV-2 among women 
and men aged 15–49 years old using a natural history 
model reflecting the clinical course of GUD following 
HSV-2 and genital HSV-1 infection with existing HSV-2 
and genital HSV-1 infection estimates for 2016.2
MeTHodS
We aimed to estimate GUD due to HSV-2 or genital HSV-1 
infection. Two different measures of GUD burden most 
relevant for public health were derived separately for HSV-2 
and genital HSV-1 infection: (1) the percentage and the 
number of people aged 15–49 years with any GUD in a given 
year; and (2) the total number of person- days with GUD 
among individuals aged 15–49 years old in a given year. The 
clinical course of infection varies between individuals (eg, 
not all individuals genitally infected with HSV experience a 
first GUD episode; and in those who do, not all have subse-
quent recurrences) and between HSV-1 and HSV-2 (HSV-2 
recurrences are more frequent than HSV-1 recurrences). 
A flow chart showing the different possible states/clinical 
courses for GUD relevant to the GUD estimates is shown 
in figure 1. The GUD burden measures therefore required 
considering and summing the percentage and time spent 
in each relevant possible GUD state. GUD burden estimates 
were generated using natural history parameter estimates 
for genital HSV-1 and HSV-2 infection (obtained from a 
literature search) with published HSV-2 and genital HSV-1 
infection estimates2 and population sizes for 2016.28
To align with our previous WHO estimates of the annual 
incidence and prevalence of HSV-2 and genital HSV-1 infec-
tion,2 we defined an individual as having ‘recently- acquired’ 
infection if up to 1 year since HSV infection acquisition, and 
as having an ‘established infection’ if more than 1 year since 
HSV acquisition. We defined a first episode of GUD as the 
first noted GUD symptoms, regardless of whether those 
symptoms occur before or after HSV seroconversion (ie, 
development of new HSV type- specific antibodies on infec-
tion). A first episode is generally thought to occur within the 
first year since HSV infection acquisition, and for the purpose 
of these estimates we assumed that the first episode always 
occurs within the first year. An occurrence of GUD symptoms 
subsequent to the first episode was termed a recurrence. For 
a full list of the definitions used, please refer to table 1.
natural history model
GUD due to HSV-2 infection
Any GUD in a given year
The percentage of people with at least one episode 
of GUD due to HSV-2 in a given year at age a (as a 
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Table 1 Definitions used
Term Definition used
Genital ulcer disease (GUD) Genital lesions, ulcers or vesicles due to either herpes simplex virus (HSV) type 2 
or genital HSV type 1.
Recently acquired infection Up to 1 year since infection was acquired.
Established infection More than 1 year since infection was acquired.
First episode First noted GUD symptoms.
Recurrence GUD symptoms subsequent to the first episode.
























 is the percentage of the population with recently 
acquired HSV-2 infection (among all individuals, not just 
those with HSV-2 infection).
 Pfirst is the percentage of individuals with recently 
acquired infection (τ≤1 year since infection) who have a 





 is the percentage of the population with estab-
lished HSV-2 infection (among all individuals, not just 
those with HSV-2 infection).
 Precurτ>1 is the percentage of individuals with established 
infection (τ>1 year since infection) who have one or 
more GUD recurrences in a year after the first year of 
infection.









  were taken from the 2016 WHO esti-
mates for HSV-2 infection prevalence and incidence, and 
 Pfirst  from studies that followed people for new HSV infec-
tion as measured by seroconversion, and then evaluated 
those people for symptoms. For  Precurτ>1 , estimates were 
informed by two types of studies:
 ► Clinic- based studies that recruited individuals with a 
diagnosed first episode due to HSV-2 and measured 
the percentage of individuals with at least one recur-
rence during follow- up.
 ► Studies that recruited individuals who were HSV-2 
seropositive but without a history of recognised 
genital herpes and observed how many experienced 
documented GUD during follow- up.
Thus, to incorporate these two types of data, we 
expanded the equation to evaluate the proportion with 
a recurrence among diagnosed individuals, θ = 1 , and 























 Pθ=1 is the percentage of individuals with HSV-2 infec-
tion who are diagnosed.
 Pθ=0 is the percentage of individuals with HSV-2 infec-
tion who are undiagnosed (equal to  1− Pθ=1 ).
To get  Pθ=1 , we used the estimate of the proportion 
of HSV-2 infections that are diagnosed from the largest 
and most recent national population- based survey for 
the USA (the country where the majority of the natural 
history studies were conducted), which is the National 
Health and Nutrition Examination Survey 2007–201018 
(online supplementary table A1). Although the propor-
tion of infected individuals who are diagnosed will vary 
widely between countries, this estimate is used here solely 
to determine the proportion of individuals to which 
clinic- based parameter data apply versus the proportion 
to which parameter data from studies of individuals with 
unrecognised infection apply.
Number of person-days with HSV GUD
The mean number of days with GUD due to HSV-2 in a 
given year at age a can be expressed by the following:
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 Tfirstτ≤1 is the number of GUD days per person with 
recently acquired infection (τ≤1) experiencing a first 
episode.
 Trecurτ≤1 is the number of GUD days per person with 
recently acquired infection (τ≤1) due to all recurrences 
in the first year (averaged over all those with recently 
acquired infection, including those without recurrences), 
among diagnosed individuals, θ = 1 , and undiagnosed 
individuals,  θ = 0 .
 Trecur1<τ≤10 is the number of GUD days per person 1<τ≤10 
years following infection due to all recurrences in a 
year (averaged over all those with established infection, 
including those without recurrences), among diagnosed 
individuals, θ = 1 , and undiagnosed individuals,  θ = 0 .
 Trecurτ>10 is the number of GUD days per person τ>10 
years following infection due to all recurrences in a 
year (averaged over all those with established infection, 
including those without recurrences), among diagnosed 
individuals, θ = 1 , and undiagnosed individuals,  θ = 0 .
Natural history parameters for those with diagnosed 
infection were obtained from clinic- based studies, while 
natural history parameters for those with undiagnosed 
infection were obtained from studies of individuals with 
unrecognised infection (online supplementary table A1).
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GUD due to HSV-1 infection
Genital HSV-1 estimates were derived in a similar 
fashion to those done for HSV-2, except that recur-
rences were limited to the first 5 years since infection 
because there is a low recurrence rate during the first 
5 years of infection and no data available for the past 
5 years. In addition, there were no identified studies of 
recurrences in those with unrecognised infection, and 
the percentage with genital HSV-1 infection who are 
diagnosed is unknown: only Pfirst can be estimated. The 















































 Precurτ>1|first is the percentage of individuals with estab-
lished infection (τ>1 year since infection) and who had a 
first episode who have one or more GUD recurrences in 
a year after the first year of infection.
 Trecurτ≤1|first is the number of GUD days per person with 
recently acquired infection (τ≤1) due to all recurrences 
in the first year among those who had a first episode 
(including those without recurrences).
 Trecurτ>1|first is the number of GUD days per person τ>1 
years following infection due to all recurrences in a year 
among those who had a first episode (including those 
without recurrences).
For more details on how all the equations were derived, 
see online supplementary appendix.
GUD estimates were derived separately by HSV type, 
WHO region (Americas, Africa, Eastern Mediterra-
nean, Europe, South- East Asia and Western Pacific), age 
and sex, and summed to generate global estimates. We 
assumed the total HSV- related GUD burden was equal to 
the sum of the burden for each of HSV-1 and HSV-2.
Literature search and pooling
Natural history parameters were informed by a PubMed 
literature search of English- language titles reporting on 
longitudinal studies (date of search: 06 November 2017). 
Data were extracted from studies which met specific inclu-
sion criteria to ensure data were comparable. Natural 
history data obtained from the literature search were then 
standardised as follows: data on episode duration ( Tfirstτ≤1  
and  Drecurτ ) reported as medians were converted to means, 
and data on recurrence frequency ( Nrecurτ ) were annual-
ised if necessary, and medians converted to means. Data 
for each parameter (separately for individuals with diag-
nosed vs undiagnosed infection, where applicable) were 
then pooled in Stata V.13.1 using meta- analysis assuming 
a random- effects model. All relevant data were pooled 
for each parameter in question: we did not perform sepa-
rate pooling by sex or geographical location for example, 
nor explore the effect of covariates on pooled estimates, 
due to limited available data. Log study estimates and the 
SE of each log estimate were used for pooling, and the 
resultant pooled estimates converted back to the natural 
scale. All natural history data were in the absence of antivi-
rals, with the exception of a few studies where antiviral use 
was unknown. A further two studies used in the pooling 
reported episodic therapy,9 29 but neither of these provided 
data on the duration of a first episode or recurrence.
Our GUD estimates follow the Guidelines for Accu-
rate and Transparent Health Estimates Reporting 
(GATHER).30 31 A completed GATHER checklist is given 
in the online supplementary appendix. Full details of 
the literature search and pooling are given in the online 
supplementary appendix. For a full list of the parameter 
values and 95% CI used in the uncertainty analysis, see 
online supplementary table A1.2 7 9 18 32–84
Sensitivity analysis
We identified three areas of uncertainty which might 
particularly influence the GUD estimates. First is uncertainty 
around how long people continue to experience HSV-2 
recurrences, since recurrence rates for the past 10 years 
were only informed by two studies (online supplementary 
table A1). Second is uncertainty around the percentage of 
the HSV-2- infected population to which recurrence rates 
as measured in clinic- based studies versus studies of unrec-
ognised infection apply. Clinic rates may be biased towards 
those with more severe disease, and studies of unrecognised 
infection miss those who have already been diagnosed 
with HSV- related GUD, which may vary by setting. Third is 
uncertainty around the percentage of the HSV-2 infected 
population that truly has HSV- related symptoms, as even 
in prospective studies of seroconversion with assessment of 
symptoms, identification of GUD is dependent on how thor-
oughly and frequently study participants are counselled, 
followed up and assessed. In a clinical trial of both women 
and men with the largest sample size in terms of number 
of HSV-2 seroconversions, and which rigorously searched 
for and evaluated those with possible HSV- related symp-
toms, 35.5% had documented first- episode GUD at any time 
around or following seroconversion.36 A sensitivity analysis 
was carried out for the HSV-2 GUD burden estimates, (1) 
limiting recurrences to the first 10 years since acquisition 
of HSV-2 infection, (2) applying recurrence natural history 
parameters from studies of those with unrecognised infec-
tion to all those with HSV-2 infection, (3) applying recur-
rence natural history parameters obtained from clinic 
studies to the maximum percentage with GUD symptoms in 
the first year as measured in a rigorous clinical trial36 (recur-
rence natural history parameters from studies of those 
with unrecognised infection not used), and (4) applying 
recurrence natural history parameters obtained from clinic 
studies to the percentage with GUD symptoms in the first 
year as measured in all studies ( Pfirst ), and recurrence natural 
history parameters from studies of those with unrecognised 
infection to all remaining infected individuals.
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Figure 2 Estimated number of people (in millions) aged 15–
49 years with any GUD due to HSV in 2016, among women 
(A) and men (B). Percentage of people with any GUD due 
to HSV in 2016 shown by the colour gradient. GUD, genital 
ulcer disease; HSV, herpes simplex virus.
uncertainty bounds
We derived 95% uncertainty intervals (UI) of the percentage 
and the number of people aged 15–49 years with any GUD 
and the total number of person- days with GUD among those 
aged 15–49 years old using a Monte Carlo sampling method 
to sample all natural history parameters in online supple-
mentary table A1 1000 times in Excel. Pooled log estimates 
and the SE of the pooled log estimate obtained from the 
meta- analysis were used for sampling and a normal distri-
bution was assumed. Uncertainty in the HSV-1 and HSV-2 
infection estimates was also incorporated by concurrently 
sampling the log force of infection using the log fitted force 
of infection and the SE of the log fitted force of infection by 
sex and WHO region, again assuming a normal distribution. 
For full details, please see the corresponding paper.2 The 
95% UI was based on the 2.5 and 97.5 percentiles from the 
set of 1000 generated GUD burden estimates.
Patient and public involvement
Patients and the public were not involved in this study.
ReSuLTS
number and percentage of people with any Gud
We estimated that 187 million people aged 15–49 years had 
at least one episode of HSV- related GUD globally in 2016, 
equivalent to 5.0% of the world’s population (figure 2). Of 
these, 178 million (95% of those with HSV- related GUD) 
had at least one episode of GUD due to HSV-2 in 2016 
(4.8%) vs 9 million (5%) due to genital HSV-1 (0.2%) 
(table 2). The burden of GUD (any HSV type) was highest 
in Africa (59 million), followed by the Western Pacific 
(39 million), the Americas (35 million) and South- East Asia 
(32 million); the burden of GUD due to HSV-1, however, 
was highest in the Americas (4 million).
The burden of GUD due to HSV-2 infection was approx-
imately double in women compared with men due to 
higher HSV-2 prevalence in women (table 2). The burden 
of GUD due to HSV-1 infection was more evenly distrib-
uted between the sexes. The burden of GUD increased 
with age for HSV-2, reflecting increased prevalence with 
age. The burden of GUD due to genital HSV-1, however, 
was highest among those aged 20–24 years and declined 
thereafter, due to the assumption that recurrences were 
limited to the first 5 years since infection.
Person-days with Gud
We estimated that there were 8300 million person- days 
spent with GUD globally in 2016 (assuming an absence 
of treatment), the vast majority of which were due to 
HSV-2 (table 3). Genital HSV-1 infection contributed 
relatively few person- days of GUD (100 million person- 
days), due to the fact that the recurrence rate was low 
for genital HSV-1 infection and limited to the first 5 years 
since infection (table 3 and online supplementary table 
A1). We estimated that the total number of first episodes 
in 2016 was approximately twice as high for HSV-2 
compared with genital HSV-1 (5.0 million vs 2.4 million, 
respectively), whereas the number of recurrences 
was markedly higher for HSV-2 than genital HSV-1 
(959 million vs 4.3 million) (online supplementary table 
A2).
We estimated that individuals with HSV-2 infection 
experienced on average 16 days with GUD in 2016 (ie, 
averaged over all those with HSV-2 infection whether 
asymptomatic or symptomatic). HSV-2 infected individ-
uals with GUD in 2016 (ie, those with symptoms), mean-
while, experienced on average 46 days with GUD. For 
genital HSV-1 infection, 0.8 days were spent with GUD 
during 2016 on average among all infected individuals, 
while infected individuals with GUD in 2016 experienced 
on average 10 days with GUD.
Sensitivity analysis
The GUD burden estimates are sensitive to the assump-
tions made. If HSV-2 recurrences are limited to the first 10 
years since infection, the percentage with any GUD due 
to HSV-2 would be lowest at 2.1% (79 million) (online 
supplementary table A3). If we assume that studies of 
those individuals with unrecognised infection represent 
everyone with HSV-2 infection in terms of recurrence 
rates and duration, then an estimate of 143 million 
(3.8%) would experience GUD. A similar percentage 
(4.1%) would experience GUD if we apply rates from 
clinic populations to the estimated maximum percentage 
with symptoms in the first year. However, if we apply rates 
from clinic populations to the average percentage with 
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symptoms in the first year, and rates from studies of those 
with unrecognised infection to everyone else, an estimate 
of 5.4% (201 million) would experience GUD.
uncertainty bounds
Taking into account uncertainty in HSV infection rates 
and GUD natural history, the 95% UI for the percentage 
of people aged 15–49 years with at least one episode 
of HSV- related GUD globally in 2016 was 3.0%–7.7% 
for HSV-2, equivalent to between 112 and 289 million 
affected people, and 0.1%–0.4% for HSV-1, equivalent 
to 5–16 million people (table 4). The 95% UI for the 
person- days spent with GUD globally in 2016 was 5500–14 
000 million person- days for HSV-2 and 60–500 million 
person- days for HSV-1. Altogether, 120–296 million 
people were estimated to have had at least one episode 
of HSV- related GUD globally in 2016 due to either HSV 
type, or between 3.2% and 7.9% of the population, equiv-
alent to 5600–14 300 million person- days of disease.
dISCuSSIon
We estimated that, in 2016, 187 million people aged 15–49 
years experienced HSV- related GUD, which was equiva-
lent to 5.0% of the world’s population. Altogether GUD 
was associated with an estimated 8300 million person- 
days with disease globally. Taking into account param-
eter uncertainty, the percentage with at least one episode 
of HSV- related GUD ranged from 3.2% to 7.9% (120–
296 million). Established (prevalent) HSV-2 infection 
caused the majority of GUD compared with both genital 
HSV-1 infection and recently acquired (incident) HSV-2 
infection, meaning GUD trends predominately reflected 
HSV-2 prevalence. This reflects the natural history of 
genital HSV infection, with HSV-2 frequently recurring 
even years after infection, while recurrences of genital 
HSV-1 infection are much less frequent. We estimated 
that 178 million people aged 15–49 years experienced 
GUD due to HSV-2 in 2016. This estimate varied between 
143 and 201 million when assumptions around the recur-
rence rate and duration were varied, and could be as 
low as 79 million if recurrences stopped after 10 years. 
Altogether in 2016 there were an estimated 5.0 million 
first episodes due to HSV-2, 2.4 million first episodes due 
to genital HSV-1, 959 million HSV-2 recurrences and 
4.3 million genital HSV-1 recurrences. Consistent with 
HSV-2 epidemiology, GUD burden was highest in Africa, 
was higher in women versus men, and increased with 
age. HSV-2 infection has been shown to increase suscep-
tibility to HIV,14 and this risk may be even higher in the 
presence of GUD.17 Therefore, the high GUD burden in 
Africa and in women is particularly concerning as young 
women in this region are at high risk of acquiring HIV.85
Strengths and limitations
This study represents the first attempt to estimate the 
burden of GUD due to HSV globally. Our study has several 
strengths. We used the most recent available WHO esti-
mates of HSV-2 and genital HSV-1 incidence and prev-
alence and the best available data on natural history 
parameters from a detailed review of the literature. By 
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reflecting the complex natural history of genital herpes 
recurrences and incorporating differences between 
HSV-1 and HSV-2 infection and by time since infection, 
we generated a useful paradigm for conceptualising the 
burden of HSV- related GUD. We were able to generate 
estimates and demonstrate patterns in GUD burden by 
HSV type, age, sex and WHO region. Importantly, we 
also considered the contribution of unrecognised infec-
tion to disease burden. By highlighting the number of 
first episodes and recurrences, our estimates can inform 
the extent to which clinical care is used currently, and 
the potential for future HSV-2 interventions to impact 
on the clinical course of infection. There is a lack of 
dependable, systematic surveillance of GUD or preva-
lence studies in most settings, and case reporting may not 
be reliable. Therefore these estimates are a first step in 
understanding the total burden of GUD, rather than just 
the limited number of cases seen in clinical care.
Our estimates have some limitations. First, we did not 
consider the effect of coinfection with HIV on GUD 
in our estimates. Our literature review identified some 
GUD natural history data for PLHIV, from which there 
was some indication that recurrence frequency and dura-
tion can be higher in those who are HIV- positive.73 86–90 
By not incorporating the effect of HIV infection on GUD, 
it is likely that we have underestimated GUD burden in 
settings with high HIV prevalence. However, to allow the 
natural history of GUD to vary by HIV status, we would 
have had to estimate the degree of coinfection, factoring 
in the epidemiological association between the two infec-
tions due to shared risk factors and biological effects of 
each infection on the other,13 91 92 and considered the 
effect of CD4 count and antiretroviral therapy status on 
GUD.90 This would have added in complexity and thus 
uncertainty, and ultimately we erred on the side of under-
estimating rather than overestimating GUD burden. Our 
natural history parameters do not account for antiviral 
use, which may have already led us to overestimate the 
number of person- days with GUD. Episodic therapy, 
which is widely used in many countries, has some effect 
on symptom duration but no effect on the likelihood 
of subsequent recurrences.55 Daily suppressive therapy, 
meanwhile, is effective at reducing symptoms and recur-
rence rate, although it is not available in most countries.93 
Another consideration is that our estimates were done at 
the WHO regional level: HIV prevalence average for the 
entire WHO Africa region was 3.9% among 15–49 years 
in 2018,94 but in South Africa for example this figure 
was 20.4%.95 The HIV–HSV-2 interaction is critically 
important and this issue should be studied in depth in 
future, dedicated analyses.
Second, the GUD estimates build on published WHO 
estimates of HSV-1 and HSV-2 infection, meaning the 
issues and assumptions affecting the infection estimates, 
including data availability, generalisability and quality, 
are carried forward to the GUD estimates.2 Furthermore, 
HSV-1 infection estimates were not produced separately by 
sex for all regions, meaning GUD estimates for HSV-1 may 
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Table 4 95% uncertainty intervals for the percentage and number (in millions) of people aged 15-49 years with any GUD 
due to HSV-2 and HSV-1 in 2016, and the number of GUD person- days (in millions) due to HSV-2 and HSV-1 among the total 
population aged 15–49 years in 2016, by sex and WHO region
WHO region Sex With any GUD (in %)
With any GUD (n) (in 
millions)
GUD person- days (in 
millions)
HSV-2
Americas Female 5.2–13.7 12.5–33.0 614–1627
Male 2.3–7.2 5.6–17.4 265–835
Africa Female 9.5–24.3 22.3–56.9 1123–2865
Male 5.4–15.2 12.5–35.5 593–1678
Eastern Mediterranean Female 1.0–6.7 1.7–11.2 82–541
Male 0.2–5.5 0.3–9.9 15–471
Europe Female 1.5–8.4 3.2–17.5 172–857
Male 0.8–4.6 1.7–9.7 84–447
South- East Asia Female 1.3–8.5 6.6–42.5 320–1989
Male 0.8–8.0 4.2–42.4 193–2055
Western Pacific Female 2.7–9.7 12.7–46.5 625–2227
Male 1.0–6.7 5.2–33.8 253–1586
Global Female 3.8–9.8 68.9–180.2 3442–8841
Male 2.0–5.9 38.8–112.9 1941–5610
Both 3.0–7.7 111.7–288.6 5507–13 990
HSV-1
Americas Female 0.5–1.2 1.2–3.0 13–89
Male 0.5–1.2 1.2–2.9 13–84
Africa Female 0.0–0.1 0.0–0.2 0–3
Male 0.0–0.1 0.0–0.2 0–3
Eastern Mediterranean Female 0.1–1.1 0.1–1.6 1–36
Male 0.1–1.1 0.1–1.8 1–38
Europe Female 0.1–0.8 0.3–1.9 3–45
Male 0.5–1.2 1.1–2.6 11–78
South- East Asia Female 0.0–0.1 0.0–0.4 0–6
Male 0.0–0.1 0.0–0.4 0–7
Western Pacific Female 0.0–0.5 0.0–2.7 0–31
Male 0.0–0.5 0.0–2.7 0–31
Global Female 0.1–0.4 2.4–7.5 26–216
Male 0.2–0.5 2.9–8.9 32–242
Both 0.1–0.4 5.3–15.8 58–455
HSV-1 and HSV-2
Global Female 4.0–10.1 73.7–184.7 3496–8897
Male 2.3–6.2 43.7–118.0 1995–5673
Both 3.2–7.9 120.0–295.6 5577–14 324
GUD, genital ulcer disease; HSV-1, herpes simplex virus type 1; HSV-2, herpes simplex virus type 2.
not fully capture differences by sex. However, the infection 
estimates were informed by systematic reviews to August 
2018 and represent the best attempt to quantify HSV-2 and 
genital HSV-1 prevalence and incidence globally by age 
and sex. In some countries, such as the USA, an ‘epide-
miological transition’ has already occurred whereby rates 
of oral HSV-1 infection during childhood have declined, 
and rates of genital HSV-1 infection have increased, due 
to decreased immunity to HSV-1 on entering adulthood 
possibly combined with increasing rates of oral sex.3 96 In 
the most recent prospective evaluation of GUD among 
women with new HSV infection, in North America, 62% 
of HSV GUD first episodes were caused by HSV-1.35 Our 
estimate for the Americas was similar, with 55% of first 
episodes due to HSV-1. Such trends may be occurring else-
where in the world.97 Although the potential for genital 
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HSV-1 infection postchildhood is uncertain, our analyses 
suggest that genital HSV-1 only makes a small contribution 
to all GUD globally, given the vastly greater number of 
HSV-2 recurrences.
Similarly, a third limitation concerns the availability, 
quality and representativeness of natural history data. 
Studies differed on a number of characteristics, including 
population group (women or men or both, or men who 
have sex with men), study location, method of identifying 
lesions (eg, clinician vs self- report) and length of follow- up. 
Pooling data from these disparate studies may have intro-
duced bias in our pooled parameter estimates; however, if 
we excluded more studies, we would have further reduced 
the availability of data, particularly for settings outside of the 
USA. The vast majority of the data on first GUD episodes 
and recurrences, which informed our natural history 
parameters, came from studies in the USA, which may not 
reflect the natural history of HSV infection elsewhere. To 
help mitigate some of these issues, we applied specific inclu-
sion and exclusion criteria for data extraction, pooled data 
from similar populations as far as possible (ie, those with 
diagnosed vs unrecognised infection), and standardised 
data prior to pooling (ie, converting medians to means, 
and calculating annualised recurrence frequencies).
In addition, the natural history data did not always 
align perfectly with the possible states for GUD. Our esti-
mate that 4.8% of the world’s population had at least one 
episode of HSV-2- related GUD globally in 2016 is equiva-
lent to 36% of those with prevalent HSV-2 infection. We 
would expect this figure not to exceed the percentage 
with a first episode (since by our definition, only those 
with a first episode can experience subsequent recur-
rences). Our pooled estimate of the percentage with a first 
episode is somewhat below this figure (21.0%). However, 
not all of the studies contributing data to this estimate 
were rigorously designed to ensure all those with GUD 
were identified: one study relied on self- reported symp-
toms, for example,37 while another only considered the 6 
months prior to seroconversion.38 Indeed, a rigorous clin-
ical trial of GUD associated with seroconversion found 
that 36% had symptoms.36 In addition, natural history 
studies may enrol people with more severe infection, 
leading to overestimates of the number and duration 
of recurrences. In our base case estimates, we used the 
method that we felt most closely aligned available data 
with the possible clinical courses for GUD. Our sensitivity 
analysis showed that the estimates were sensitive to the 
relative percentages that recurrence rates from clinic- 
based studies and studies of unrecognised infection are 
applied to. Therefore, new studies of the natural history 
among all those with HSV-2 infection would be useful.
Fourth, we assumed that both the percentage who 
experience one or more recurrences in a given year after 
the first year and the duration of a recurrence are inde-
pendent of time since infection (generating one pooled 
recurrence duration estimate using data with any time 
since infection), although we did allow the recurrence 
rate to vary over time. The one available study which 
examined recurrence frequency and duration over a 
wide range of time since infection found no change in 
recurrence frequency but a small decline in recurrence 
duration, leading to an overall decline in the percentage 
of days with GUD.64 Our pooled parameter estimate 
for the mean number of days with recurrent GUD due 
to HSV-2 was actually slightly increased for longer time 
since infection (although 95% CI had a large overlap), 
perhaps because of the disparate studies combined, 
or perhaps because we did not account for decreasing 
recurrence duration over time. Therefore we may have 
overestimated GUD burden, as our sensitivity analysis 
showed that the burden would be lower if recurrences 
stopped after more than 10 years since acquisition of 
HSV-2 infection. However, we also did not consider GUD 
burden in those aged 50 years or over, potentially leading 
to an underestimation of burden overall rather than an 
overestimation. We estimated that individuals with HSV-2 
infection experience on average 16 days with GUD annu-
ally. Recurrence data from a study excluded from the 
pooling because it was among all those who are HSV-2 
seropositive (including those who were asymptomatic) 
found a median number of annual recurrences of 2.1,98 
which when applied to estimates of the mean recurrence 
duration for those who are HSV-2 seropositive (data 
also unused), which ranged from 7 to 10 days,99–101 gives 
an estimate of 15–21 days with GUD annually, which is 
similar to our estimate of 16 days.
Finally, we did not consider the modifying effect of 
previous HSV-1 infection on GUD due to HSV-2. Prior 
studies have shown that existing HSV-1 infection has 
no effect on subsequent HSV-2 acquisition,102 but that 
those with pre- existing HSV-1 infection are more likely 
to have asymptomatic HSV-2 acquisition compared with 
those who are HSV-1 seronegative.9 The recurrence rate 
is similar among symptomatic people with and without 
HSV-1 infection.42 54 For the purposes of this exercise, 
we assumed an absence of interactions between HSV-1 
and HSV-2, which may have led to a slight overestimation 
of GUD among those with coinfection. Given that the 
number of people affected by GUD due to genital HSV-1 
is small relative to HSV-2, we also assumed that total GUD 
burden is simply the sum of GUD burden for HSV-2 and 
GUD burden for genital HSV-1. We further assumed that 
among HSV-2 seropositive persons, all GUD was related 
to HSV-2 infection. Some studies of HSV-2 recurrence 
rate may have inadvertently captured some GUD due 
to genital HSV-1. However, given that studies specific 
to HSV-1 found low genital HSV-1 recurrence rates, 
and HSV-1 infection only rarely follows HSV-2,9 this was 
unlikely to have been a significant limitation. We further 
assumed no contribution to GUD from non- HSV aetiol-
ogies in those with genital HSV infection. The inclusion 
of non- HSV- attributable GUD could potentially have 
led to an overestimation of GUD due to HSV, but this 
is unlikely to have been a major issue given the types of 
studies contributing data, many of which were rigorous 
clinical trials.
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ConCLuSIonS
Up to 187 million people aged 15–49 years may experience 
HSV- related GUD annually, with women disproportion-
ately affected, and the highest burden of GUD in Africa. 
This large burden is a public health concern in itself, but 
especially so since HIV and GUD are similarly distributed 
across populations, maximising the biological potential for 
GUD to increase both susceptibility to, and transmissibility 
of, HIV.13 15 16
Our estimates do not provide insight into the severity of 
symptoms beyond frequency and duration of recurrences. 
GUD can have a substantial impact on the lives of those 
it affects, not only in terms of physical pain and discom-
fort, but also psychosocially.8 103 At the same time, many 
people with HSV GUD do not recognise they have herpes 
and never seek care for their symptoms. Better data are 
needed on how the GUD burden estimated here translates 
into overall impact on quality of life in terms of quality- 
adjusted or disability- adjusted life years.104 In the mean 
time, the substantial burden of GUD can be ameliorated 
by antivirals, which are not widely used worldwide for HSV- 
related GUD. Accessibility to antivirals, along with accu-
rate diagnostics, therefore needs to be increased in order 
to improve the lives of the millions of people with GUD 
globally.93 Our estimates also show that new interventions 
such as prophylactic or therapeutic HSV vaccines, new 
antivirals that can suppress the virus, or microbicides may 
have a large public health potential to reduce GUD both by 
reducing the frequency of symptoms in the millions of indi-
viduals who already have GUD and also perhaps by having 
a meaningful impact on the transmission of infection and 
subsequent GUD.
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